TaiGen Biopharmaceuticals Holdings Limited (TPEX:4157)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
9.45
-0.27 (-2.78%)
May 8, 2026, 1:30 PM CST
Market Cap6.73B +2.4%
Revenue (ttm)259.47M +72.2%
Net Income45.18M
EPS0.06
Shares Out711.83M
PE Ratio157.50
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,714,268
Average Volume1,344,625
Open9.72
Previous Close9.72
Day's Range9.44 - 9.84
52-Week Range7.44 - 16.40
Beta0.24
RSI28.53
Earnings DateMay 13, 2026

About TPEX:4157

TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. Its product pipeline comprises Taigexyn, which is in phase II clinical trial for the treatment of community-acquired pneumonia/diabetic foot infection; TG-1000, which is in phase III clinical trial to treat influenza A and B; TG-4318; ISM-4808 to treat CKD anemia; Furaprevir, a HCV pro... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2001
Country Cayman Islands
Stock Exchange Taipei Exchange
Ticker Symbol 4157
Full Company Profile

Financial Performance

Financial Statements